New Ways to Read Cancer's DNA Patterns
Statistical methods for cancer mutational signatures
This project creates better computer tools to understand the unique DNA changes found in cancer cells, helping us learn more about how cancer develops.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Dana-Farber Cancer Inst NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project ID | NIH-11099940 on NIH RePORTER |
What this research studies
Cancer cells have unique changes in their DNA, like a fingerprint, caused by things like carcinogens or how the cancer grows. This project is building advanced computer models to better read and understand these DNA fingerprints, called mutational signatures. These new tools will help scientists uncover more about what causes cancer and how it progresses. The team will also create a free software package so other researchers can use these powerful methods. This work is closely connected to efforts at Dana-Farber to understand multiple myeloma.
Who could benefit from this research
Good fit: Patients with cancer, particularly those with multiple myeloma, whose tumor DNA is being sequenced for research purposes, might indirectly benefit from the improved analysis of their cancer's unique genetic changes.
Not a fit: Patients not involved in genomic sequencing research or those with conditions unrelated to cancer mutational signatures would not directly benefit from this specific statistical methods development.
Why it matters
Potential benefit: If successful, this work could lead to a deeper understanding of cancer causes and progression, potentially guiding more effective prevention or treatment strategies in the future.
How similar studies have performed: While initial successes in mutational signature analysis exist, this project aims to significantly advance the statistical tools available, addressing current limitations and expanding the scope of what can be learned.
Where this research is happening
Boston, United States
- Dana-Farber Cancer Inst — Boston, United States (Active)
Researchers
- Principal investigator: Parmigiani, Giovanni Luigi — Dana-Farber Cancer Inst
- Study coordinator: Parmigiani, Giovanni Luigi
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.